The device was received for analysis.Both leads were still attached to the pacemaker.Prior to the analysis of the pacemaker, the quality documents accompanying the manufacturing process for this device were re-investigated and all production steps were performed accordingly.Particularly the final acceptance test proved the device functions to be as specified.Upon receipt, the pacemaker was interrogated, and the memory content was analyzed indicating no anomalies.The battery status was found to be larger than 80 percent.The archive device data documented that capture control was activated.On (b)(6) 2022 at 00:34 am the automatic right ventricular threshold measurement revealed a threshold of 1.3 v.At 08:31 pm loss of capture detections were noted which led to an automatic threshold adaptation to 4.2 v.The device was re-programmed manually to higher pacing output at 11:19 pm.Several at episodes were documented in the devices data which occurred on (b)(6) 2022.During the further course of the analysis, the header of the device was analyzed.The set screws could be easily screwed in and out, there was no foreign material inside the header bores.All dimensions of the header bores were within the range requested by the standard specifications.Also, the spring elements of the pacemaker did not show any deviations.The ability of the device to deliver therapies was verified.The anti-bradycardia pacing pulses proved to be normal and in amplitude and frequency as programmed.There was no indication of a device malfunction.An additional long-term pacing test was initiated.During the test, each pacing pulse was recorded.The evaluation of these pacing pulses documented regular device behavior.There was no intermittent or permanent loss of output.In conclusion, the device is fully functional.The analysis did not show any deviations from the technical specifications.The analysis did not reveal any sign of a material or manufacturing problem.
|